Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (***Currently amended***) A haptotactic-peptide liposomal composition comprising an isolated haptotactic peptide consisting of ~~from 21 to 40 amino acids comprising~~ SEQ ID NO:1 and at least one liposome, wherein the haptotactic peptide induces cell attachment to the composition, and wherein the at least one liposome has at least one lipid bilayer enclosing an aqueous compartment.

2-6. (***Cancelled***)

7. (***Previously presented***) The composition of claim 1 characterized in that uptake of the haptotactic-peptide-liposomal composition by mammalian endothelial or fibroblast cells is enhanced at least 2 fold compared to the uptake of said liposomes absent said haptotactic peptide.

8. (***Previously presented***) The composition of claim 1 wherein the liposomes comprise at least one member selected from the group consisting of: phospholipids of natural or synthetic origin; phospholipids combined with polyethylene glycol; phospholipids combined with glycerides; phosphor amino lipids cerebroglucosides and gangliosides.

9. (***Previously presented***) The composition of claim 1 wherein the liposomes further comprise at least one biologically active compound.

10. (***Previously presented***) The composition of claim 9 wherein the at least one biologically active compound is selected from the group consisting of polynucleotides, proteins, peptides, polysaccharides, hormones, drugs, steroids, fluorescent dyes and radioactive markers.

11. (***Previously presented-withdrawn***) A method for enhancing liposome uptake into cells, comprising contacting cells with the haptotactic peptide-liposomal composition of claim 1, wherein liposomal uptake by the cells is enhanced at least two fold compared to the uptake of said liposomes absent the haptotactic peptide.

12. (***Previously presented-withdrawn***) The method of claim 11 wherein the haptotactic peptide- liposomal composition is produced *ab initio* with at least one type of haptide.

13. (***Previously presented-withdrawn***) The method of claim 11 wherein the haptotactic peptide- liposomal composition is produced extemporaneously using preformed vesicles combined with at least one type of haptide.

14. (***Previously presented-withdrawn***) The method of claim 12 wherein the haptotactic peptide- liposomal composition is further produced by the method comprising dispersing lipophilic and amphiphilic components and at least one type of haptotactic peptide in an aqueous solution.

15-19. (***cancelled***)

20. (***previously presented-withdrawn***) The method of claim 11 wherein the lipid phase of the liposomes comprises at least one member of the group consisting of phospholipids of natural or synthetic origin; phospholipids combined with polyethylene glycol; phospholipids combined with glycerides; phosphoaminolipids cerebroglucosides and gangliosides.

21. (***previously presented-withdrawn***) The method of claim 11 wherein the cells are chosen from mammalian cells and cells from mesenchymal origin.

22. (***previously presented-withdrawn***) A method for enhancing intracellular uptake of biologically active compounds characterized by low-permeability through the cell membrane the method comprising contacting cells with the haptotactic peptide-liposomal composition of claim 9, wherein the uptake of said biologically active compounds is enhanced at least two fold

compared to the uptake of said biologically active compounds detached from said haptotactic peptide-liposomal composition.

23. (***previously presented-withdrawn***) The method of claim 22 wherein the haptotactic peptide-liposomal composition is produced *ab initio* with at least one type of haptide and at least one biologically active molecule.

24. (***previously presented-withdrawn***) The method of claim 22 wherein the haptotactic peptide-liposomal composition is produced extemporaneously using preformed vesicles comprising at least one biologically active molecule combined with at least one haptide.

25. (***previously presented-withdrawn***) The method of claim 23 wherein the haptotactic peptide- liposomal composition is further produced by the method comprising dispersing lipophilic and amphiphilic components, at least one haptotactic peptide and at least one biologically active molecule in an aqueous solution.

26-30. (***cancelled***)

31. (***previously presented-withdrawn***) The method of claim 22 wherein the lipid phase of the liposomes comprises at least one member of the group consisting of phospholipids of natural or synthetic origin; phospholipids combined with polyethylene glycol; phospholipids combined with glycosides; phosphoaminolipids cerebroglucosides and gangliosides.

32. (***previously presented-withdrawn***) The method of claim 22 wherein the cells are chosen from mammalian cells and cells from mesenchymal origin.

33. (***previously presented-withdrawn***) The method of claim 22 wherein the biologically active compound within the liposomes is selected form the group consisting of polynucleotides, proteins, peptides, polysaccharides, hormones, drugs, steroids, fluorescent markers and radioactive markers.

34. (***Previously presented***) A pharmaceutical composition comprising the haptotactic peptide-liposomal composition according to claim 1, wherein the liposomes comprise at least one active ingredient having a diagnostic or therapeutic activity, and wherein said liposomes are formulated in a pharmaceutically acceptable diluent or carrier.

35. (***Previously presented***) The pharmaceutical composition of claim 34 wherein the at least one active ingredient is selected from the group consisting of a cytotoxic compound, a cytostatic compound, an antisense compound, an anti-viral agent, a specific antibody and an imaging agent.

36. (***Previously presented***) A cosmetic composition comprising the haptotactic peptide-liposomal composition according to claim 1, wherein the liposomes comprise at least one active ingredient having a beneficial cosmetic effect.

37. (***previously presented-withdrawn***) A method for enhancing the delivery of a therapeutic agent into cells comprising the step of administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition according to claim 34 wherein the at least one active ingredient has therapeutic activity.

38. (***previously presented-withdrawn***) The method of claim 37 wherein the administering step is performed parenterally, topically, orally or by inhalation.

39. (***previously presented-withdrawn***) A method for enhancing the delivery of a diagnostic agent into cells comprising the step of administering to a subject in need thereof a diagnostically effective amount of the pharmaceutical composition of claim 34, wherein the at least one active ingredient has diagnostic activity.

40. (***previously presented-withdrawn***) The method of claim 39 wherein the administering step is performed parenterally, topically or orally.

41. (***previously presented-withdrawn***) A method for enhancing the delivery of an active ingredient having a beneficial cosmetic effect into cells comprising the step of administering to a subject in need thereof the cosmetic composition of claim 36.

42. (***cancelled***)

43. (***previously presented-withdrawn***) The method of claim 41 wherein the administering step is performed topically.

44-47. (***cancelled***)

48. (***Previously presented***) The composition of claim 1, wherein said at least one liposome is classified as small unilamellar vesicle, a large unilamellar vesicle, a reverse phase evaporation vesicle, a multilamellar large vesicle, or oligolamellar vesicle.

49. (***Previously presented***) The composition of claim 8, wherein the at least one liposome further comprises a natural or synthetic cholesterol.

50. (***previously presented-withdrawn***) The method of claim 21, wherein the mammalian cells are leukocytes.

51. (***previously presented-withdrawn***) The method of claim 21, wherein the cells from mesenchymal origin or chosen from astrocytes, chondrocytes, dendritic cells, endothelial cells, fibroblasts, glial cells, neurons, kidney cells, liver cells, melanocytes, mesenchymal cells, myofibroblasts, monocytes, parenchymal cells, pancreatic cells, smooth muscle cells, thyroid cells, malignant and transformed cells.